August 2019 Vol 10, No 8

Fear and anxiety are unwelcome, although inevitable, occurrences in the initial phases of a cancer diagnosis and can certainly rear their ugly heads again and again along a patient’s journey.
Pembrolizumab as second-line therapy improved overall survival (OS) in patients with advanced or metastatic esophageal cancer and high PD-L1 expression compared with chemotherapy, according to findings from the phase 3 KEYNOTE-181 study presented at the 2019 Gastrointestinal Cancers Symposium.
Adjuvant treatment with durvalumab, a checkpoint inhibitor, in patients with residual disease after trimodal therapy for advanced esophageal or gastroesophageal junction (GEJ) adenocarcinoma was associated with a 79% 1-year relapse-free survival rate in a phase 2 clinical trial.
The era of immunotherapy has opened new perspectives in renal cell carcinoma (RCC), which is one of the tumors most highly infiltrated with cluster of differentiation T cells and PD-1 expression, partially accounting for its sensitivity to immunotherapy.
First-line therapy with pembrolizumab plus axitinib significantly improved overall survival (OS), progression-free survival (PFS), and objective response rates compared with standard-of-care sunitinib in patients with clear cell metastatic renal cell carcinoma (RCC) in KEYNOTE-426.
The combination of the PD-1 inhibitor durvalumab and the CTLA-4 inhibitor tremelimumab added to best supportive care improved overall survival (OS) by >2 months compared with best supportive care alone in a phase 2 randomized trial of unselected patients with refractory colorectal cancer (CRC).

Results 1 - 10 of 10

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code